All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Lisocabtagene maraleucel receives EC approval for the treatment of adult patients with R/R LBCL after one prior therapy
On May 3, 2023, it was announced that lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, received approval from the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B (FL3B) after one prior therapy.1
This approval is based on results from the phase III TRANSFORM trial (NCT03575351),1 in which liso-cel was compared with standard therapy. Below, we report the key data:
- In an interim analysis with median follow up of 6.2 months, event-free survival (EFS) for liso-cel compared with standard therapy was 10.1 months vs 2.3 months, respectively (HR, 0.349; 95% confidence interval [CI], 0.229–0.530; p < 0.0001).1
- In the primary analysis at a median follow-up of 17.5 months, EFS was not reached for liso-cel vs 2.4 months for standard therapy (95% CI, 9.5–NR vs 2.2–4.9).1
- Liso-cel achieved a complete response rate of 73.9% compared with 43.5% for standard therapy.1
- Median progression-free survival was not met (95% CI, 12.6–NR) for liso-cel vs 6.2 months (95% CI, 4.3–8.6) for standard therapy (HR, 0.400; 95% CI, 0.261–0.615).1
Liso-cel showed improved EFS compared to standard of care with a manageable safety profile.1 These data support the use of liso-cel as a second-line treatment for patients with primary refractory or early relapsed LBCL.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
